Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Research

ExxonMobil Expanding New Jersey Research and Engineering Center in Clinton

Clinton, NJ, October 19, 2017 — ExxonMobil announced on October 13 that it has broken ground on the expansion of its research facility in Clinton, NJ, a key center of innovation that supports the company’s broad research and development programs.

Expansion of the facility, home to ExxonMobil’s fundamental and process research and development, including advancing algae biofuel and carbon capture technologies, is expected to be completed in 2019 and will include employees relocating from its research facility in Paulsboro, NJ. Continue reading

HINJ Hosts Life Sciences Celebration 2017; Honors Six for Meritorious Contributions

New Brunswick, NJ, October 13, 2017 ― Celebrating its 20th anniversary, the HealthCare Institute of New Jersey (HINJ) yesterday morning honored four individuals, a nonprofit patient advocacy organization and a public high school for their meritorious contributions in public service, medical innovation/human health, patient access/advocacy and STEM education.

The recipients of HINJ’s fifth annual honors — presented at the Historic Trenton Masonic Temple — were:

The Honorable Bob Franks Public Service Award

The Honorable Diane Allen
Member, New Jersey Senate (Burlington)

HINJ honored Senator Allen for her nearly 22 years of distinguished legislative service that has earned her a reputation as being one of the most effective patient advocates in the New Jersey Senate.  In the past year alone, Senator Allen, who will retire from the Senate in January, authored laws relating to elder abuse; domestic violence; improved support for veterans challenged with addiction and mental health issues; and the expansion of telemedicine, which is revolutionizing patient access to health care. Continue reading

PhRMA’s Chief Medical Officer on ‘The Next Five Years of PDUFA VI: Driving the Availability of Innovative Treatments for Patients’

Dr. Bill Chin

Washington, DC, October 13, 2017William “Bill” Chin, M.D., who serves as the chief medical officer of Pharmaceutical Research and Manufacturers of America (PhRMA) and leads the Scientific & Regulatory Advocacy department as executive vice president, wrote the following on PhRMA’s blog, The Catalyst, on October 2:

Yesterday, October 1, marked the first day of implementation for PDUFA VI, the next iteration of the Prescription Drug User Fee Act (PDUFA) and one of the best tools that the U.S. Food and Drug Administration (FDA) has for enhancing regulatory efficiency and encouraging innovative development of safe and effective new medicines for patients.

First enacted in 1992, PDUFA allows the FDA to collect user fees from biopharmaceutical companies to help support the agency’s process for review of new drugs and biologics. Continue reading

PhRMA Announces 2017 Research & Hope Award Honorees; Releases ‘Medicines in Development for Mental Illnesses Report’

Washington, DC, October 11, 2017 — As part of Mental Health Awareness Week, Pharmaceutical Research and Manufacturers of America (PhRMA) yesterday announced it is recognizing and honoring five individuals who are working tirelessly to advocate for patients, fight stigma surrounding mental illnesses and advance research at our 2017 Research & Hope Awards.

In addition, PhRMA said that America’s biopharmaceutical companies are committed to alleviating the considerable burden of mental illness and bringing cutting-edge medicines and new treatments to patients.

According to a new report — “Medicines in Development for Mental Illnesses 2017 Report” — released on October 10, there are more than 140 medicines in development to treat mental illnesses such as anxiety, depression, schizophrenia and more. Continue reading

Hackensack University Medical Center Foundation Receives Donation from Celgene to Advance Multiple Myeloma Research at John Theurer Cancer Center

Former Roche campus to be new Seton Hall-Hackensack Meridian School of Medicine

Hackensack, NJ, October 11, 2017 — The Hackensack University Medical Center Foundation announced on October 5 that it has received a substantial donation from Celgene Corporation to advance multiple myeloma research and transformational medicine that improve patient outcomes at Hackensack Meridian Health–John Theurer Cancer Center.

Supported by Celgene, a global biopharmaceutical leader in the discovery, development and delivery of treatment for diseases like multiple myeloma (MM), funds will help to establish the Multiple Myeloma Institute (MMI) — a leading-edge research facility at the Seton Hall-Hackensack Meridian School of Medicine scheduled to open in 2018.

Celgene and John Theurer Cancer Center are accomplished leaders in developing novel therapies for patients with multiple myeloma. Continue reading

THURSDAY MORNING! Join HINJ for 2017 Life Sciences Celebration in Trenton; Six Honorees Named

New Brunswick, NJ, October 10, 2017 ― The HealthCare Institute of New Jersey (HINJ) will honor meritorious leadership in and contributions to New Jersey’s life sciences community at HINJ’s Life Sciences Celebration 2017, which will be held Thursday, October 12 from 8:00 to 10:00 a.m. at the Historic Trenton Masonic Temple, 100 Barrack Street, Trenton.

Online registration for the free event is now open.

HINJ’s 2017 honorees are: Continue reading

Rutgers Research: Creating Brain Cells to Detect Tourette’s; First to Use Genetic Engineering Technique to Investigate Disease

New Brunswick, NJ, September 25, 2017 — Robin Lally reports that scientists at Rutgers University-New Brunswick are the first to use a genetic engineering technique to create brain cells from the blood cells of individuals in a three-generation family with Tourette syndrome to help determine what causes the disease.

“This is so important to the future research of Tourette’s and other neuropsychiatric disorders because before this technique was discovered we were unable to study brain-type nerve cells of living patients,” said Jay Tischfield, senior author of the study published in Molecular Psychiatry and MacMillan Distinguished Professor of Genetics.  Continue reading

PhRMA ‘Pipeline’ Report: 74 Percent of Medicines in Development Have Potential to Be First-in-Class Treatments

Washington, DC, September 26, 2017 — Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a new report by The Analysis Group, Inc. commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).

“The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development” report examines the global state of the drug development pipeline and provides insights into new approaches biopharmaceutical researchers are pursuing.

The pipeline report, which updates a previous analysis, highlights new treatment approaches such as cell therapy and gene therapy, as well as DNA or RNA therapeutics and conjugated monoclonal antibodies. Continue reading

Rutgers Research: Cloning Thousands of Genes for Massive Protein Libraries

New Brunswick, NJ, September 18, 2017 — Discovering the function of a gene requires cloning a DNA sequence and expressing it.  Until now, this was performed on a one-gene-at-a-time basis, causing a bottleneck.

Scientists at Rutgers University-New Brunswick in collaboration with Johns Hopkins University and Harvard Medical School have invented a technology to clone thousands of genes simultaneously and create massive libraries of proteins from DNA samples, potentially ushering in a new era of functional genomics. Continue reading

PhRMA Releases ‘Research in Your Backyard’ for New Jersey; PhRMA, HINJ and WWFH-NJ Host Discussion Focused on Biopharma Research in Garden State

New Brunswick, NJ, September 16, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on June 28 released a new report entitled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in New Jersey,” which finds that 25,127 patients participated in clinical trials around the state in 2013, generating an estimated economic impact of $617 million.

The report was released at an event co-hosted by PhRMA, the HealthCare Institute of New Jersey (HINJ) and We Work for Health New Jersey (WWFH-NJ) that was held at the Rutgers Cancer Institute of New Jersey on June 28.

In addition to a presentation of the new PhRMA report, the event featured a panel discussion of industry experts that was moderated by HINJ President and Chief Executive Officer Dean J. Paranicas.  The panelists were: Continue reading